Amr Conventions Research Ltd

1. Allergan Inc. $291,949 61 payments
2. Supernus Pharmaceuticals, Inc. $229,685 34 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $137,710 143 payments
4. Otsuka Pharmaceutical Development & Commercialization, Inc. $26,927 3 payments
5. AbbVie, Inc. $24,064 2 payments
6. Shire North American Group Inc $17,246 12 payments

1. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $155,005 29 payments
2. A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $125,111 120 payments
3. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficithyperactivity Disorder $105,808 12 payments
4. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $90,828 13 payments
5. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $66,714 10 payments
6. A Double Blind, Placebo- and Active Controlled Evaluation of the Safety and Efficacy of Levomilnacipran Er in Adolescent Patients With Major Depressive Disorder $41,354 10 payments
7. Assessment of Efficacy and Safety of Spn-810 for the Treatment of Impulsive Aggression Ia in Adolescent Subjects With Attention Deficithyperactivity Disorder Adhd in Conjunction With Standard Adhd Treatment $27,361 6 payments
8. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $20,377 1 payment
9. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $16,418 5 payments
10. Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficithyperactivity Disorder Adhd $13,354 6 payments

1. Patient care $81,628 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.